(firstQuint)Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 in Hepatitis C-infected Patients.

 First-in-humans, phase 1, dose-escalation study with 4 dose levels of single-agent IMO-2125.

 Patients will proceed through a screening period, treatment period, and follow-up period of approximately 4 months' duration.

 There will be 4 dose cohorts including active drug and placebo dosing.

.

 Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 in Hepatitis C-infected Patients@highlight

First-in-humans, phase 1, dose-escalation study with 4 dose levels of single-agent IMO-2125.

